arrow_back Trending Legislation
Share share

Affordable Prescriptions Act: Prohibiting Product Hopping

This bill amends the Federal Trade Commission Act to prohibit "product hopping." This practice involves withdrawing a reference drug or making changes that impede competition from generic and biosimilar drugs.
Key points
Defines and prohibits "hard" and "soft" switches by manufacturers that impede competition from generic or biosimilar alternatives.
Authorizes the Federal Trade Commission (FTC) to seek equitable remedies, including disgorgement of unjust enrichment and restitution, from violators.
Limits the number of patents (to 20) that a reference product sponsor can assert in infringement actions against biosimilar applicants.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Affordable Prescriptions for Patients Act of 2021
Print number: S 1435
Sponsor: Sen. Cornyn, John [R-TX]
Process start date: 2021-04-28
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-3-pro-preview
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Affordable Prescriptions Act: Prohibiting Product Hopping

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 1435.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-04-28.

What are the main provisions?

Key points include:

  • Defines and prohibits "hard" and "soft" switches by manufacturers that impede competition from generic or biosimilar alternatives.
  • Authorizes the Federal Trade Commission (FTC) to seek equitable remedies, including disgorgement of unjust enrichment and restitution, from violators.
  • Limits the number of patents (to 20) that a reference product sponsor can assert in infringement actions against biosimilar applicants.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Cornyn, John [R-TX].

What is the latest detailed status?

The latest detailed status is: Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-01-02.

Analysis and Potential Impact of S 1435

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health Courts and Law Economy